As for immunotherapy, PD-1/PD-L1 inhibitors, such as pembrolizumab and nivolumab, are being investigated in combination with other targeted therapies, like BRAF inhibitors, to improve the immune response in patients with refractory thyroid cancer. This evidence concerns the gene BRAF and thyroid gland carcinoma.